|
1
|
Nagase H and Woessner JF Jr: Matrix
metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar
|
|
2
|
Pilka R, Norata GD, Domanski H, Andersson
C, Hansson S, Eriksson P and Casslen B: Matrix metalloproteinase-26
(matrilysin-2) expression is high in endometrial hyperplasia and
decreases with loss of histological differentiation in endometrial
cancer. Gynecol Oncol. 94:661–670. 2004. View Article : Google Scholar
|
|
3
|
Park HI, Ni J, Gerkema FE, Liu D,
Belozerov VE and Sang QX: Identification and characterization of
human endometase (Matrix metalloproteinase-26) from endometrial
tumor. J Biol Chem. 275:20540–20544. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stetler-Stevenson WG, Aznavoorian S and
Liotta LA: Tumor cell interactions with the extracellular matrix
during invasion and metastasis. Annu Rev Cell Biol. 9:541–573.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Murray GI, Duncan ME, O’Neil P, Melvin WT
and Fothergill JE: Matrix metalloproteinase-1 is associated with
poor prognosis in colorectal cancer. Nat Med. 2:461–462. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
7
|
Chambers AF and Matrisian LM: Changing
views of the role of matrix metalloproteinases in metastasis. J
Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sternlicht MD, Lochter A, Sympson CJ, et
al: The stromal proteinase MMP3/stromelysin-1 promotes mammary
carcinogenesis. Cell. 98:137–146. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Velasco G, Pendas AM, Fueyo A, Knauper V,
Murphy G and Lopez-Otin C: Cloning and characterization of human
MMP-23, a new matrix metalloproteinase predominantly expressed in
reproductive tissues and lacking conserved domains in other family
members. J Biol Chem. 274:4570–4576. 1999. View Article : Google Scholar
|
|
10
|
de Coignac AB, Elson G, Delneste Y, et al:
Cloning of MMP-26. A novel matrilysin-like proteinase. Eur J
Biochem. 267:3323–3329. 2000.PubMed/NCBI
|
|
11
|
Marchenko GN, Ratnikov BI, Rozanov DV,
Godzik A, Deryugina EI and Strongin AY: Characterization of matrix
metalloproteinase-26, a novel metalloproteinase widely expressed in
cancer cells of epithelial origin. Biochem J. 356:705–718. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Uria JA and Lopez-Otin C: Matrilysin-2, a
new matrix metalloproteinase expressed in human tumors and showing
the minimal domain organization required for secretion, latency,
and activity. Cancer Res. 60:4745–4751. 2000.
|
|
13
|
Trabert B, Wentzensen N, Yang HP, Sherman
ME, Hollenbeck AR, Park Y and Brinton LA: Is estrogen plus
progestin menopausal hormone therapy safe with respect to
endometrial cancer risk? Int J Cancer. 132:417–426. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Isaka K, Nishi H, Nakai H, Nakada T, Feng
Li Y, Ebihara Y and Takayama M: Matrix metalloproteinase-26 is
expressed in human endometrium but not in endometrial carcinoma.
Cancer. 97:79–89. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cooke PS, Buchanan DL, Young P, et al:
Stromal estrogen receptors mediate mitogenic effects of estradiol
on uterine epithelium. Proc Natl Acad Sci USA. 94:6535–6540. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pierro E, Minici F, Alesiani O, et al:
Stromal-epithelial interactions modulate estrogen responsiveness in
normal human endometrium. Biol Reprod. 64:831–838. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li W, Savinov AY, Rozanov DV, et al:
Title: Matrix metalloproteinase-26 is associated with
estrogen-dependent malignancies and targets α1-antitrypsin serpin.
Cancer Res. 64:8657–8665. 2004.PubMed/NCBI
|
|
18
|
Isaka K, Nishi H, Sagawa Y, et al:
Establishment of a new human cell line (EN) with TP53 mutation
derived from endometrial carcinoma. Cancer Genet Cytogenet.
141:20–25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishida M: The Ishikawa cells from birth
to the present. Hum Cell. 15:104–117. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mak HY and Parker MG: Use of suppressor
mutants to probe the function of estrogen receptor-p160 coactivator
interactions. Mol Cell Biol. 21:4379–4390. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Banno K, Kisu I, Yanokura M, et al:
Progestin therapy for endometrial cancer: the potential of
fourth-generation progestin (Review). Int J Oncol. 40:1755–1762.
2012.PubMed/NCBI
|
|
22
|
Xiong Y, Dowdy SC, Eberhardt NL, Podratz
KC and Jiang SW: hMLH1 promoter methylation and silencing in
primary endometrial cancers are associated with specific
alterations in MBDs occupancy and histone modifications. Gynecol
Oncol. 103:321–328. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tashiro H, Blazes MS, Wu R, et al:
Mutations in PTEN are frequent in endometrial carcinoma but rare in
other common gynecological malignancies. Cancer Res. 57:3935–3940.
1997.PubMed/NCBI
|
|
24
|
Lax SF, Kendall B, Tashiro H, Slebos RJ
and Hedrick L: The frequency of p53, K-ras mutations, and
microsatellite instability differs in uterine endometrioid and
serous carcinoma: evidence of distinct molecular genetic pathways.
Cancer. 88:814–824. 2000. View Article : Google Scholar
|
|
25
|
Kawaguchi M, Banno K, Yanokura M, et al:
Analysis of candidate target genes for mononucleotide repeat
mutation in microsatellite instability-high (MSI-H) endometrial
cancer. Int J Oncol. 35:977–982. 2009.PubMed/NCBI
|
|
26
|
Suprun HZ, Taendler-Stolero R, Schwartz J
and Ettinger M: Experience with Endopap endometrial sampling in the
cytodiagnosis of endometrial carcinoma and its precursor lesions. I
A correlative cytologic-histologic-hysteroscopic diagnostic pilot
study. Acta Cytol. 38:319–323. 1994.
|
|
27
|
Foulks MJ: The Papanicolaou smear: its
impact on the promotion of women’s health. J Obstet Gynecol
Neonatal Nurs. 27:367–373. 1998.
|
